Search

01/12/2021 First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met
Majem, M, Sullivan, I, Viteri, S, Lopez-Vivanco, G, Cobo, M, Sanchez, JM, Garcia-Gonzalez, J, Garde, J, Sampayo, M, Martrat, G, Malfettone, A, Karachaliou, N, Molina-Vila, MA, Rosell, R. First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. EUROPEAN JOURNAL OF CANCER. 2021; 159DOI:10.1016/j.ejca.2021.09.039. PMID:34763195. IF:10.002(Q1/2D).
01/11/2021 Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy
Cortellini, A, Ricciuti, B, Facchinetti, F, Alessi, JVM, Venkatraman, D, Dall'Olio, FG, Cravero, P, Vaz, VR, Ottaviani, D, Majem, M, Piedra, A, Sullivan, I, Lee, KA, Lamberti, G, Hussain, N, Clark, J, Bolina, A, Barba, A, Benitez, JC, Gorria, T, Mezquita, L, Hoton, D, Nana, FA, Besse, B, Awad, MM, Pinato, DJ. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. ANNALS OF ONCOLOGY. 2021; 32(11)DOI:10.1016/j.annonc.2021.08.1744. PMID:34400292. IF:51.769(Q1/1D).
01/11/2021 Paired Somatic-Germline Testing of 15 Polyposis and Colorectal Cancer-Predisposing Genes Highlights the Role of APC Mosaicism in de Novo Familial Adenomatous Polyposis
Rofes, P, Gonzalez, S, Navarro, M, Moreno-Cabrera, JM, Solanes, A, Darder, E, Carrasco, E, Iglesias, S, Salinas, M, Gomez, C, Velasco, A, Tuset, N, Varela, M, Llort, G, Cajal, TRY, Grau, E, Duenas, N, Merlano, ND, Matias-Guiu, X, Rivera, B, Balmana, J, Pineda, M, Brunet, J, Capella, G, del Valle, J, Lazaro, C. Paired Somatic-Germline Testing of 15 Polyposis and Colorectal Cancer-Predisposing Genes Highlights the Role of APC Mosaicism in de Novo Familial Adenomatous Polyposis. JOURNAL OF MOLECULAR DIAGNOSTICS. 2021; 23(11)DOI:10.1016/j.jmoldx.2021.07.024. PMID:34454113. IF:5.341(Q1/3D).
01/11/2021 Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
Gronchi, A, Miah, AB, DeiTos, AP, Abecassis, N, Bajpai, J, Bauer, S, Biagini, R, Bielack, S, Blay, JY, Bolle, S, Bonvalot, S, Boukovinas, I, Bovee, JVMG, Boye, K, Brennan, B, Brodowicz, T, Buonadonna, A, DeAlava, E, Del Muro, XG, Dufresne, A, Eriksson, M, Fagioli, F, Fedenko, A, Ferraresi, V, Ferrari, A, Frezza, AM, Gasperoni, S, Gelderblom, H, Gouin, F, Grignani, G, Haas, R, Hassan, AB, Hecker-Nolting, S, Hindi, N, Hohenberger, P, Joensuu, H, Jones, RL, Jungels, C, Jutte, P, Kager, L, Kasper, B, Kawai, A, Kopeckova, K, Krakorova, DA, Le Cesne, A, LeGrange, F, Legius, E, Leithner, A, Lopez-Pousa, A, Martin-Broto, J, Merimsky, O, Messiou, C, Mir, O, Montemurro, M, Morland, B, Morosi, C, Palmerini, E, Pantaleo, MA, Piana, R, Piperno-Neumann, S, Reichardt, P, Rutkowski, P, Safwat, AA, Sangalli, C, Sbaraglia, M, Scheipl, S, Schoffski, P, Sleijfer, S, Strauss, D, Strauss, S, SundbyHall, K, Trama, A, Unk, M, VandeSande, MAJ, VanderGraaf, WTA, van Houdt, WJ, Frebourg, T, Casali, PG, Stacchiotti, S, ESMO Guidelines Comm, EURACAN, GENTURIS. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY. 2021; 32(11)DOI:10.1016/j.annonc.2021.07.006. PMID:34303806. IF:51.769(Q1/1D).
01/11/2021 The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis
Dabush, DR, Shepshelovich, D, Shochat, T, Tibau, A, Amir, E, Goldvaser, H. The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis. CANCER TREATMENT REVIEWS. 2021; 100DOI:10.1016/j.ctrv.2021.102293. PMID:34543860. IF:13.608(Q1/1D).
01/11/2021 Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
Casarrubios, M, Cruz-Bermudez, A, Nadal, E, Insa, A, Campelo, MDG, Lazaro, M, Domine, M, Majem, M, Rodriguez-Abreu, D, Martinez-Marti, A, de Castro-Carpeno, J, Cobo, M, Lopez-Vivanco, G, Del Barco, E, Caro, RB, Vinolas, N, Aranda, IB, Viteri, S, Massuti, B, Barquin, M, Laza-Briviesca, R, Sierra-Rodero, B, Parra, ER, Sanchez-Espiridion, B, Rocha, P, Kadara, H, Wistuba, II, Romero, A, Calvo, V, Provencio, M. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. CLINICAL CANCER RESEARCH. 2021; 27(21)DOI:10.1158/1078-0432.CCR-21-1200. PMID:34376534. IF:13.801(Q1/1D).
01/11/2021 A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
Wu, YL, Tsuboi, M, John, T, Grohe, C, Majem, M, Goldman, JW, Laktionov, K, Kim, SW, Kato, T, Vu, HV, Lu, S, Lee, KY, Akewanlop, C, Yu, CJ, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Zeng, LM, Hodge, R, Atasoy, A, Rukazenkov, Y, Herbst, RS. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncology. 2021; 17(35)DOI:10.2217/fon-2021-0752. PMID:34723634. IF:3.674(Q3/7D).
01/11/2021 A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study
Bancroft, EK, Page, EC, Brook, MN, Thomas, S, Taylor, N, Pope, J, McHugh, J, Jones, AB, Karlsson, Q, Merson, S, Ong, KR, Hoffman, J, Huber, C, Maehle, L, Grindedal, EM, Stormorken, A, Evans, DG, Rothwell, J, Lalloo, F, Brady, AF, Bartlett, M, Snape, K, Hanson, H, James, P, McKinley, J, Mascarenhas, L, Syngal, S, Ukaegbu, C, Side, L, Thomas, T, Barwell, J, Teixeira, MR, Izatt, L, Suri, M, Macrae, FA, Poplawski, N, Chen-Shtoyerman, R, Ahmed, M, Musgrave, H, Nicolai, N, Greenhalgh, L, Brewer, C, Pachter, N, Spigelman, AD, Azzabi, A, Helfand, BT, Halliday, D, Buys, S, Cajal, TRY, Donaldson, A, Cooney, KA, Harris, M, McGrath, J, Davidson, R, Taylor, A, Cooke, P, Myhill, K, Hogben, M, Aaronson, NK, Ardern-Jones, A, Bangma, CH, Castro, E, Dearnaley, D, Dias, A, Dudderidge, T, Eccles, DM, Green, K, Eyfjord, J, Falconer, A, Foster, CS, Gronberg, H, Hamdy, FC, Johannsson, O, Khoo, V, Lilja, H, Lindeman, GJ, Lubinski, J, Axcrona, K, Mikropoulos, C, Mitra, AV, Moynihan, C, Raghallaigh, HN, Rennert, G, Collier, R, Offman, J, Kote-Jarai, Z, Eeles, RA. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. LANCET ONCOLOGY. 2021; 22(11)DOI:10.1016/S1470-2045(21)00522-2. PMID:34678156. IF:54.433(Q1/1D).